A carregar...
Cost-effectiveness of pazopanib versus sunitinib for metastatic renal cell carcinoma in the United Kingdom
BACKGROUND: Sunitinib and pazopanib are the only two targeted therapies for the first-line treatment of locally advanced or metastatic renal cell carcinoma (mRCC) recommended by the United Kingdom’s National Institute for Health and Care Excellence. Pazopanib demonstrated non-inferior efficacy and a...
Na minha lista:
| Publicado no: | PLoS One |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Public Library of Science
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5479501/ https://ncbi.nlm.nih.gov/pubmed/28636648 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0175920 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|